The Study
Renal tubular toxicity of HMG-CoA reductase inhibitors.
This is like telling a story about one person who got sick after taking a medicine, felt better when they stopped, and got sick again when they tried it again. It's interesting, but we can't be sure the medicine caused the problem — it might have been something else.
Analysis score
Maximum 30 for a case report.
Where the score came from
A person took a strong cholesterol medicine and their kidneys got hurt. When they stopped, the kidneys got better. When they took it again, the kidneys got hurt again.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 520 / 100
Quality score
Detailed descriptions of individual patients or small groups. Valuable for identifying new conditions or side effects, but cannot establish generalizable conclusions.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This shows the medicine might harm kidneys in some people, but we don't know how often.
- 2One person had kidney problems after taking high-dose statin.
- 3Problems went away when they stopped.
- 4Came back after 2 weeks when they tried again.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Year
2004
Authors
R. van Zyl-Smit, J. Firth, M. Duffield, A. Marais
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.